WO2001092304A3 - Transporters and ion channels - Google Patents

Transporters and ion channels Download PDF

Info

Publication number
WO2001092304A3
WO2001092304A3 PCT/US2001/017065 US0117065W WO0192304A3 WO 2001092304 A3 WO2001092304 A3 WO 2001092304A3 US 0117065 W US0117065 W US 0117065W WO 0192304 A3 WO0192304 A3 WO 0192304A3
Authority
WO
WIPO (PCT)
Prior art keywords
ion channels
trich
transporters
provides
polynucleotides
Prior art date
Application number
PCT/US2001/017065
Other languages
French (fr)
Other versions
WO2001092304A2 (en
Inventor
Michael Thornton
Narinder K Chawla
Henry Yue
Danniel B Nguyen
Preeti Lai
Ameena R Gandhi
Catherine M Tribouley
Monique G Yao
Original Assignee
Incyte Genomics Inc
Michael Thornton
Narinder K Chawla
Henry Yue
Danniel B Nguyen
Preeti Lai
Ameena R Gandhi
Catherine M Tribouley
Monique G Yao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Michael Thornton, Narinder K Chawla, Henry Yue, Danniel B Nguyen, Preeti Lai, Ameena R Gandhi, Catherine M Tribouley, Monique G Yao filed Critical Incyte Genomics Inc
Priority to AU2001265002A priority Critical patent/AU2001265002A1/en
Priority to US10/297,022 priority patent/US20030216310A1/en
Priority to CA002410084A priority patent/CA2410084A1/en
Priority to EP01939490A priority patent/EP1320548A2/en
Priority to JP2002500915A priority patent/JP2004512016A/en
Publication of WO2001092304A2 publication Critical patent/WO2001092304A2/en
Publication of WO2001092304A3 publication Critical patent/WO2001092304A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The invention provides human transporters and ion channels (TRICH) and polynucleotides which identify and encode TRICH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TRICH.
PCT/US2001/017065 2000-05-26 2001-05-25 Transporters and ion channels WO2001092304A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2001265002A AU2001265002A1 (en) 2000-05-26 2001-05-25 Transporters and ion channels
US10/297,022 US20030216310A1 (en) 2001-05-25 2001-05-25 Transporters and ion channels
CA002410084A CA2410084A1 (en) 2000-05-26 2001-05-25 Transporters and ion channels
EP01939490A EP1320548A2 (en) 2000-05-26 2001-05-25 Transporters and ion channels
JP2002500915A JP2004512016A (en) 2000-05-26 2001-05-25 Transporters and ion channels

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US20842400P 2000-05-26 2000-05-26
US60/208,424 2000-05-26
US20900100P 2000-06-01 2000-06-01
US60/209,001 2000-06-01
US21058800P 2000-06-08 2000-06-08
US60/210,588 2000-06-08
US21233500P 2000-06-16 2000-06-16
US60/212,335 2000-06-16
US21374700P 2000-06-22 2000-06-22
US60/213,747 2000-06-22
US21539100P 2000-06-29 2000-06-29
US60/215,391 2000-06-29

Publications (2)

Publication Number Publication Date
WO2001092304A2 WO2001092304A2 (en) 2001-12-06
WO2001092304A3 true WO2001092304A3 (en) 2003-03-06

Family

ID=27559000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/017065 WO2001092304A2 (en) 2000-05-26 2001-05-25 Transporters and ion channels

Country Status (5)

Country Link
EP (1) EP1320548A2 (en)
JP (1) JP2004512016A (en)
AU (1) AU2001265002A1 (en)
CA (1) CA2410084A1 (en)
WO (1) WO2001092304A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1538161A3 (en) * 1999-09-24 2005-06-15 Human Genome Sciences, Inc. 32 human secreted proteins
AU2001278076A1 (en) * 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
US20020076780A1 (en) * 2000-08-16 2002-06-20 Turner C. Alexander Novel human ion channel proteins and polynucleotides encoding the same
US20020172998A1 (en) * 2000-09-25 2002-11-21 Millennium Pharmaceuticals, Inc. 32612, a novel human peptide transporter and uses therefor
US20030166522A1 (en) * 2000-12-12 2003-09-04 Ketchum Karen A. Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1356049A2 (en) * 2000-12-15 2003-10-29 Millennium Pharmaceuticals, Inc. Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
EP1358330A2 (en) * 2001-02-09 2003-11-05 Incyte Genomics, Inc. Transporters and ion channels
GB2375349A (en) * 2001-02-13 2002-11-13 Glaxo Group Ltd Chloride intracellular channel-related proteins
AU2002367140A1 (en) * 2001-12-27 2003-07-15 Takeda Chemical Industries, Ltd. Human sglt homolog promoter and use thereof
WO2003072751A2 (en) * 2002-02-25 2003-09-04 Vanderbilt University Expression system for human brain-specific voltage-gated sodium channel, type 1
AU2003275713A1 (en) * 2002-10-29 2004-05-25 Takeda Pharmaceutical Company Limited Use of sglt homolog
EP1613649A2 (en) * 2003-04-04 2006-01-11 Ingenium Pharmaceuticals AG Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2332906A (en) * 1997-11-20 1999-07-07 Hoffmann-La Roche Ag Nucleic acids encoding TTX-resistant Na channel proteins
WO2000003015A2 (en) * 1998-07-10 2000-01-20 Incyte Pharmaceuticals, Inc. Human transport protein homologs
WO2001014547A1 (en) * 1999-08-20 2001-03-01 Active Pass Pharmaceuticals, Inc. Novel abc transporter and uses thereof
WO2001066732A1 (en) * 2000-03-06 2001-09-13 Merck Patent Gmbh Human abc transporter expressed in liver, atil

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2332906A (en) * 1997-11-20 1999-07-07 Hoffmann-La Roche Ag Nucleic acids encoding TTX-resistant Na channel proteins
WO2000003015A2 (en) * 1998-07-10 2000-01-20 Incyte Pharmaceuticals, Inc. Human transport protein homologs
WO2001014547A1 (en) * 1999-08-20 2001-03-01 Active Pass Pharmaceuticals, Inc. Novel abc transporter and uses thereof
WO2001066732A1 (en) * 2000-03-06 2001-09-13 Merck Patent Gmbh Human abc transporter expressed in liver, atil

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALLIKMETS ET AL.: "Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using expressed sequence tags database", HUM MOL GENET, vol. 5, no. 10, 1996, pages 1649 - 1655, XP002177318 *
COOPER E C ET AL: "Ion channel genes and human neurological disease: Recent progress, prospects, and challenges", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 9, 27 April 1999 (1999-04-27), pages 4759 - 4766, XP002174532, ISSN: 0027-8424 *
DATABASE EM_HTG [online] EMBL; 26 March 1997 (1997-03-26), ALLIKMETS ET AL.: "Homo sapiens clone EST45597 mRNA sequence", XP002205424, retrieved from EBI accession no. HSU66673 Database accession no. U66673 *
DATABASE EM_HUM [online] EMBL; 21 November 2000 (2000-11-21), EMADI-KONJIN ET AL.: "Homo sapiens ATP-binding cassette half-transporter (PRP) mRNA, complete cds.", XP002205429, retrieved from EBI Database accession no. AF308472 *
DATABASE EM_HUM [online] EMBL; 28 June 2000 (2000-06-28), HIRSCH-ERNST ET AL.: "Homo sapiens mRNA for ABC transporter umat (ABCB6 gene)", XP002205427, retrieved from EBI accession no. HSA289233 Database accession no. AJ289233 *
DATABASE EM_HUM [online] EMBL; 5 August 1998 (1998-08-05), ANDERSSON ET AL.: "Homosapiens clone 24410 ABC transporter mRNA, partial cds.", XP002205425, retrieved from EBI Database accession no. AF070598 *
DATABASE SWALL [online] 1 March 2001 (2001-03-01), EMADI-KONJIN ET AL.: "ATP-binding cassette half-transporter", XP002205428, retrieved from EBI Database accession no. Q9HAQ7 *
DATABASE SWALL [online] 16 October 2001 (2001-10-16), MITSUHASHI ET AL.: "ATP-binding cassette, sub-family B, member 6, ....", XP002205426, retrieved from EBI accession no. ABC6_HUMAN Database accession no. Q9NP58 *
IBBERSON M ET AL: "GLUTX1, A NOVEL MAMMALIAN GLUCOSE TRANSPORTER EXPRESSED IN THE CENTRAL NERVOUS SYSTEM AND INSULIN-SENSITIVE TISSUES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 7, 18 February 2000 (2000-02-18), pages 4607 - 4612, XP000971734, ISSN: 0021-9258 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 23, 9 June 2000 (2000-06-09), pages 17536 - 17540, XP002151661 *

Also Published As

Publication number Publication date
CA2410084A1 (en) 2001-12-06
EP1320548A2 (en) 2003-06-25
AU2001265002A1 (en) 2001-12-11
JP2004512016A (en) 2004-04-22
WO2001092304A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
WO2002004520A3 (en) Transporters and ion channels
WO2001046258A3 (en) Transporters and ion channels
WO2003093444A3 (en) Transporters and ion channels
WO2002012340A3 (en) Transporters and ion channels
WO2001098468A3 (en) Proteases
WO2002040541A3 (en) Transporters and ion channels
WO2002063005A3 (en) Lipid-associated molecules
WO2002008396A3 (en) Human proteases
WO2002022684A3 (en) Transporters and ion channels
WO2001092304A3 (en) Transporters and ion channels
WO2001062923A3 (en) Transporters and ion channels
WO2002083712A8 (en) Transporters and ion channels
WO2001077174A3 (en) Human transporters and ion channels
WO2002026950A3 (en) Transferases
WO2002077237A3 (en) Transporters and ion channels
WO2001096546A3 (en) Protein phosphatases
WO2003083085A3 (en) Transporters and ion channels
WO2001085942A3 (en) Cytoskeleton-associated proteins
WO2002010363A3 (en) Protein phosphatases
WO2001071004A3 (en) Proteases
WO2003016493A3 (en) Transporters and ion channels
WO2002002757A3 (en) Adenylyl and guanylyl cyclases
WO2002024924A3 (en) Protein phosphatases
WO2002020736A3 (en) Proteases
WO2002002633A3 (en) Transporters and ion channels

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2001939490

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2410084

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10297022

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001939490

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001939490

Country of ref document: EP